Voya Investment Management LLC Grows Stock Holdings in Intuitive Surgical, Inc. (NASDAQ:ISRG)

Voya Investment Management LLC boosted its stake in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG - Free Report) by 6.6% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 1,110,574 shares of the medical equipment provider's stock after purchasing an additional 68,311 shares during the period. Intuitive Surgical comprises 0.6% of Voya Investment Management LLC's portfolio, making the stock its 25th largest holding. Voya Investment Management LLC owned about 0.31% of Intuitive Surgical worth $579,533,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in ISRG. Howard Capital Management Group LLC increased its holdings in Intuitive Surgical by 4.5% during the third quarter. Howard Capital Management Group LLC now owns 2,125 shares of the medical equipment provider's stock valued at $1,044,000 after buying an additional 92 shares during the last quarter. Principal Financial Group Inc. raised its holdings in Intuitive Surgical by 1.5% in the 3rd quarter. Principal Financial Group Inc. now owns 602,393 shares of the medical equipment provider's stock worth $295,938,000 after purchasing an additional 9,194 shares during the period. World Investment Advisors LLC purchased a new position in Intuitive Surgical during the third quarter valued at $228,000. Arvest Bank Trust Division bought a new stake in Intuitive Surgical during the third quarter valued at about $260,000. Finally, Wilmington Savings Fund Society FSB increased its position in Intuitive Surgical by 15,322.2% in the third quarter. Wilmington Savings Fund Society FSB now owns 555,661 shares of the medical equipment provider's stock worth $272,980,000 after buying an additional 552,058 shares in the last quarter. Hedge funds and other institutional investors own 83.64% of the company's stock.

Intuitive Surgical Price Performance

Shares of Intuitive Surgical stock traded down $0.71 during trading on Tuesday, hitting $513.30. The stock had a trading volume of 489,846 shares, compared to its average volume of 1,611,698. The stock has a market cap of $182.83 billion, a PE ratio of 80.10, a PEG ratio of 5.85 and a beta of 1.55. Intuitive Surgical, Inc. has a 12 month low of $367.39 and a 12 month high of $616.00. The firm's fifty day simple moving average is $510.03 and its 200-day simple moving average is $533.26.

Intuitive Surgical (NASDAQ:ISRG - Get Free Report) last issued its quarterly earnings results on Tuesday, April 22nd. The medical equipment provider reported $1.81 earnings per share for the quarter, topping the consensus estimate of $1.71 by $0.10. Intuitive Surgical had a return on equity of 14.55% and a net margin of 27.81%. The firm had revenue of $2.25 billion for the quarter, compared to the consensus estimate of $2.19 billion. During the same period in the prior year, the business posted $1.50 earnings per share. Analysts expect that Intuitive Surgical, Inc. will post 6.43 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of equities research analysts have commented on ISRG shares. Bernstein Bank raised their target price on shares of Intuitive Surgical from $655.00 to $700.00 and gave the stock an "overweight" rating in a research note on Monday, January 27th. Piper Sandler decreased their price objective on shares of Intuitive Surgical from $670.00 to $575.00 and set an "overweight" rating on the stock in a research report on Wednesday, April 23rd. Raymond James upped their target price on shares of Intuitive Surgical from $560.00 to $688.00 and gave the stock an "outperform" rating in a report on Friday, January 24th. Evercore ISI dropped their price target on Intuitive Surgical from $510.00 to $470.00 and set an "in-line" rating for the company in a research note on Wednesday, April 23rd. Finally, Robert W. Baird reduced their price objective on shares of Intuitive Surgical from $600.00 to $575.00 and set an "outperform" rating on the stock in a research report on Wednesday, April 23rd. Five investment analysts have rated the stock with a hold rating and fifteen have given a buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average price target of $598.95.

Insider Activity

In other news, EVP Robert Desantis sold 11,545 shares of the stock in a transaction on Thursday, March 13th. The stock was sold at an average price of $499.22, for a total transaction of $5,763,494.90. Following the transaction, the executive vice president now owns 5,224 shares of the company's stock, valued at approximately $2,607,925.28. This represents a 68.85 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Jamie Samath sold 94 shares of the business's stock in a transaction dated Wednesday, January 29th. The shares were sold at an average price of $571.11, for a total transaction of $53,684.34. Following the completion of the sale, the chief financial officer now owns 2,630 shares of the company's stock, valued at approximately $1,502,019.30. This represents a 3.45 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 30,819 shares of company stock valued at $15,937,836. 0.70% of the stock is currently owned by company insiders.

About Intuitive Surgical

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.